Clinical Trials Logo
NCT number NCT01788007
Study type Interventional
Source Taro Pharmaceuticals USA
Status Completed
Phase Phase 1
Start date January 2013
Completion date December 2013
View Details

Clinical Trial Summary

The objective of this study is to compare the relative efficacy and safety of the test formulation Imiquimod 3.75% Topical Cream to the marketed formulation Zyclara® (imiquimod) 3.75% Topical Cream in the treatment of actinic keratosis. Both the test and reference formulations will also be compared to a placebo cream to test for superiority.

Clinical Trial Description


Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
See also
Status Clinical Trial Phase
 Recruiting NCT02674048 - Metvix Daylight PDT in Actinic Keratosis N/A
 Recruiting NCT02421471 - PMS to Evaluate the Safety and Efficacy of Picato® Gel N/A
 Active, not recruiting NCT02239679 - Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + ALA Photodynamic Therapy Phase 2
 Completed NCT01966120 - Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis With Photodynamic Therapy Phase 3
 Completed NCT01686152 - Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis Phase 3
 Active, not recruiting NCT01525329 - Combination Therapy With 5-FU and PDT for the Treatment of Post-transplant Premalignant Skin Disease Phase 3
 Completed NCT01444989 - Development and Validation of a Quality of Life Instrument for Actinic Keratosis N/A
 Completed NCT01449513 - PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy Phase 1
 Terminated NCT01203878 - Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Phase 4
 Completed NCT00989313 - A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study Phase 3
 Completed NCT00306800 - Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp Phase 3
 Completed NCT00375739 - Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses Phase 2
 Active, not recruiting NCT02611804 - A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp Phase 3
 Completed NCT02289768 - Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses Phase 3
 Completed NCT02325661 - Open Uncontrolled Validation Study for the German Version of the Actinic Keratosis Quality of Life Questionnaire (AKQoL) N/A
 Completed NCT02019355 - Actinic Keratosis Study Phase 0
 Completed NCT02120898 - A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses Phase 3
 Completed NCT01922050 - A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis Phase 1/Phase 2
 Withdrawn NCT01735942 - Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions Phase 0
 Completed NCT01742663 - A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis Phase 1